Your browser doesn't support javascript.
Prostate cancer: a risk factor for COVID-19 in males?: A protocol for systematic review and meta analysis.
Mou, Ruiyu; Jin, Xinyao; Li, Wenjie; Wu, Mingxin; Liu, Xiaodi; Liu, Zhao; Guo, Shanqi; Li, Xiaojiang; Jia, Yingjie.
  • Mou R; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Jin X; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome.
  • Li W; Evidence-based Medicine Center of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Wu M; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Liu X; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Liu Z; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Guo S; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Li X; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.
  • Jia Y; Tianjin Key Laboratory of Translational Research of TCM Prescription and Syndrome.
Medicine (Baltimore) ; 99(43): e22591, 2020 Oct 23.
Artículo en Inglés | MEDLINE | ID: covidwho-933920
ABSTRACT

INTRODUCTION:

COVID-19 is now a global pandemic. Although there are very few studies describing the characteristics of SARS-CoV-2 infections in patients with prostate cancer, these patients are likely to be more susceptible to COVID-19 than healthy people because of their immunosuppressed state. However, there is no evidence that prostate cancer is a risk factor for COVID-19.

METHODS:

We searched the Wanfang database, the China Science Journal Citation Report (VIP database), the China National Knowledge Infrastructure (CNKI), Web of Science, EMBASE, PubMed, and the Cochrane Library for studies related to the topic. We designed a standardized data extraction sheet and used Epidata software 3.1 for data extraction. In accordance with the Cochrane 5.1.0 standard, both a quality assessment and a risk assessment were carried out for the research meeting the inclusion criteria. The data were analyzed using Revman 5.3 and Stata 13.0 software.

RESULTS:

The study integrated existing research findings and a meta-analysis of the data to investigate the prevalence of prostate cancer in males infected with SARS-CoV-2 and the adverse clinical outcomes in male patients with or without COVID-19.

CONCLUSION:

The results of this research may provide a basis for judging if prostate cancer is a risk factor for males infected with SARS-CoV-2, and the findings can effectively help to prevent COVID-19 in patients with prostate cancer. ETHICS AND DISSEMINATION Ethics approval is not required for this systematic review as it will involve the collection and analysis of secondary data. The results of the review will be reported in international peer-reviewed journals PRORPERO REGISTRATION NUMBER CRD42020194071.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Neoplasias de la Próstata / Infecciones por Coronavirus / Betacoronavirus Tipo de estudio: Estudios diagnósticos / Estudio observacional / Estudio pronóstico / Revisiones / Revisión sistemática/Meta análisis Tópicos: Covid persistente Límite: Humanos / Masculino Idioma: Inglés Revista: Medicine (Baltimore) Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Neoplasias de la Próstata / Infecciones por Coronavirus / Betacoronavirus Tipo de estudio: Estudios diagnósticos / Estudio observacional / Estudio pronóstico / Revisiones / Revisión sistemática/Meta análisis Tópicos: Covid persistente Límite: Humanos / Masculino Idioma: Inglés Revista: Medicine (Baltimore) Año: 2020 Tipo del documento: Artículo